Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a strategic drug discovery and development partnership with Celgene Corporation to identify therapeutics in oncology; and a strategic alliance with Novo Nordisk A/S to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities; collaboration with Sanofi to develop LAB031, which accelerates drug discovery across various therapeutic areas; and a strategic research collaboration with Almirall, S.A. to discover and develop first-in-class therapeutics in the field of dermatology diseases, as well as strategic collaboration agreement with Centogene AG. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.
Industry, Sector and Symbol
Stock Exchange ETR
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolETR:EVT
Previous Symbol
CUSIPN/A
Phone+49-40-560810
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees2,268
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Evotec (ETR:EVT) Frequently Asked Questions
What is Evotec's stock symbol?
Evotec trades on the ETR under the ticker symbol "EVT."
What price target have analysts set for EVT?
3 brokers have issued 1 year price targets for Evotec's shares. Their forecasts range from €20.00 to €26.00. On average, they expect Evotec's share price to reach €22.33 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for Evotec.
What is the consensus analysts' recommendation for Evotec?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evotec.
Has Evotec been receiving favorable news coverage?
Media headlines about EVT stock have trended somewhat negative on Thursday, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evotec earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Evotec's key competitors?
Some companies that are related to Evotec include Acerus Pharmaceuticals (ASP), Aequus Pharmaceuticals (AQS), Amryt Pharma (AMYT), Aphria (APH), Aurora Cannabis (ACB), Bausch Health Companies (BHC), Benchmark (BMK), Biosyent (RX), Cannabis Science (CBIS), Canopy Growth (WEED), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF), Cipher Pharmaceuticals (CPH) and Cosmos (COSM).
Who are Evotec's key executives?
Evotec's management team includes the folowing people:
- Dr. Werner Lanthaler, CEO & Member of Management Board (Age 50)
- Mr. Enno Spillner, CFO & Member of Management Board (Age 48)
- Dr. Mario Polywka, COO & Member of Management Board (Age 55)
- Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 54)
- Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
What is Evotec's stock price today?
One share of EVT stock can currently be purchased for approximately €19.50.
What is Evotec's official website?
How can I contact Evotec?
Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.
MarketBeat Community Rating for Evotec (ETR EVT)
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
